<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1692-7273</journal-id>
<journal-title><![CDATA[Revista Ciencias de la Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Cienc. Salud]]></abbrev-journal-title>
<issn>1692-7273</issn>
<publisher>
<publisher-name><![CDATA[Editorial Universidad del Rosario]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1692-72732021000300055</article-id>
<article-id pub-id-type="doi">10.12804/revistas.urosario.edu.co/revsalud/a.10532</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Evaluation of Differences in Metabolic and Immunologic Markers and Cardiovascular Risk in HIV-1 Patients]]></article-title>
<article-title xml:lang="es"><![CDATA[Evaluación de la relación entre marcadores metabólicos, inmunológicos y de riesgo cardiovascular en pacientes con VIH-1]]></article-title>
<article-title xml:lang="pt"><![CDATA[Avaliação da relação entre marcadores metabólicos, imunológicos e de risco cardiovascular em pacientes com HIV-1]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro MD, MSc]]></surname>
<given-names><![CDATA[Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[León MSc]]></surname>
<given-names><![CDATA[Kevin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marín-Palma MSc]]></surname>
<given-names><![CDATA[Damariz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Oyuela MD]]></surname>
<given-names><![CDATA[Sarita M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cataño-Bedoya MD, Esp]]></surname>
<given-names><![CDATA[Jhon Ubeimar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Duque-Botero MD, Esp]]></surname>
<given-names><![CDATA[Julieta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Giraldo-Méndez MD, Esp.]]></surname>
<given-names><![CDATA[Diana Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Taborda Sci Doc]]></surname>
<given-names><![CDATA[Natalia A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernandez Sci Doc]]></surname>
<given-names><![CDATA[Juan C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rugeles Sci Doc]]></surname>
<given-names><![CDATA[María Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jaimes MD, Esp., MSC, PhD]]></surname>
<given-names><![CDATA[Fabián Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia Faculty of Medicine ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Cooperativa de Colombia Faculty of Medicine ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital San Vicente Fundación  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Corporación Universitaria Remington Facultad de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>19</volume>
<numero>3</numero>
<fpage>55</fpage>
<lpage>72</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S1692-72732021000300055&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S1692-72732021000300055&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S1692-72732021000300055&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  HIV infection induces an exacerbated chronic inflammatory response, which triggers metabolic disorders and cardiovascular diseases; however, there are individuals, known as HIV controllers, who do not have typical progression markers. As cardiovascular risk tests are not accurate on HIV-1 infected patients, the study of metabolic and inflammatory parameters in individuals with different patterns of progression could contribute to the definition of predictors of cardiovascular disease in this population. The aim of this study was to compare HIV controllers and HIV progressors (with and without antiretroviral therapy) as well as with healthy controls in order to explore differences and correlations in metabolic and inflammatory biomarkers associated with cardiovascular risk.  Materials and methods:  This was a cross-sectional analytical study which included 63 individuals infected with HIV-1 classified as HIV controllers or progressors (with or without antiretroviral therapy), and a healthy control group. The following parameters were determined: carotid intima-media thickness (CIMT); cardiovascular risk scores; lipid profile, fasting glucose, high-sensitivity CRP, D-dimer, sCD14, sCD163, IL-6, and IL-18. Data were compared with Anova or Kruskal-Wallis, and correlations were evaluated by the Spearman coefficient.  Results:  While there were no significant differences in Framingham, DAD or CIMT values, HIV controllers exhibited lower triglycerides levels when compared with HIV progressors. No differences were observed in markers, such as high-sensitivity CRP, IL-6, IL-18, and sCD163, among the groups. The median HDL value was higher in HIV progressors on antiretroviral therapy, and CIMT in HIV controllers was negatively correlated with sCD14.  Conclusion:  HIV controllers have a different cardiovascular profile than HIV progressors according to their values in metabolic and immunological biomarkers.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  la infección por VIH-1 induce una respuesta inflamatoria crónica exacerbada que desencadena alteraciones metabólicas y cardiovasculares; sin embargo, algunos individuos "controladores" no presentan los marcadores de progresión típicos. Dado que las pruebas que evalúan el riesgo cardiovascular carecen de precisión en pacientes con VIH-1, el estudio de parámetros inflamatorios en individuos con diferente progresión podría aportar a la definición de predictores de enfermedad cardiovascular en esta población. El objetivo es explorar diferencias y correlaciones en biomarcadores metabólicos e inflamatorios asociados con riesgo cardiovascular, comparando individuos controladores y progresores con y sin terapia antiviral.  Materiales y métodos:  estudio analítico transversal con 63 individuos infectados por VIH-1, clasificados en controladores y progresores (con terapia antiviral y sin esta), y controles sanos. Se midió el grosor de la íntima media carotidea (CIMT), puntajes de riesgo cardiovascular y cuantificación de perfil lipídico, glucemia en ayunas, PCR ultrasensible, dímero D, sCD14, sCD163, IL-6 e IL-18. Se realizó comparación por Anova o Kruskal-Wallis y correlación por coeficiente de Spearman.  Resultados:  no hubo diferencias significativas en índices de Framingham, DAD o CIMT, pero los individuos controladores presentaron menores valores de triglicéridos, comparados con los progresores. No se observaron diferencias en PCR ultrasensible, IL-6, IL-18, y sCD163, entre los grupos estudiados. La mediana del HDL fue mayor en los progresores con terapia antiviral y el CIMT en los controladores se correlacionó negativamente con sCD14.  Conclusión:  los individuos controladores presentan un perfil cardiovascular diferente a los individuos progresores, de acuerdo con los biomarcadores metabólicos e inmunológicos evaluados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  a infecção pelo HIV-1 induz resposta inflamatória crônica exacerbada, que desencadeia alterações metabólicas e doenças cardiovasculares; no entanto, existem indivíduos, chamados controladores, que não possuem os marcadores de progressão típicos. Tendo em vista que os testes que avaliam o risco cardiovascular carecem de precisão em pacientes com HIV-1, o estudo de parâmetros metabólicos e inflamatórios em indivíduos com diferentes padrões de progressão pode contribuir para a definição de preditores de doença cardiovascular nessa população. O objetivo é explorar diferenças e correlações em biomarcadores metabólicos e inflamatórios associados ao risco cardiovascular, comparando indivíduos controladores e progressores submetidos ou não à terapia antiviral.  Materiais e métodos:  Estudo analítico transversal que incluiu 63 indivíduos infectados pelo HIV-1, classificados como controladores e progressores (com e sem terapia antiviral), além de grupos controle saudáveis. Realizou-se a medição da espessura da íntima média da carótida (CIMT), pontuações de risco cardiovascular; e quantificação do perfil lipídico, glicemia em jejum, PCR ultrassensível, dímero D, sCD14, sCD163, IL-6 e IL-18. A comparação foi feita por Anova ou teste de Kruskal-Wallis e a correlação pelo coeficiente de Spearman.  Resultados.  Embora não tenha havido diferenças significativas nos índices de Framingham, DAD ou CIMT, os indivíduos controladores apresentaram valores de triglicerídeos mais baixos, em comparação com os progressores. Não foram observadas diferenças em marcadores como PCR ultrassensível, IL-6, IL-18 e sCD163, entre os grupos estudados. O HDL médio foi maior em indivíduos progressores em terapia antiviral, e o CIMT em indivíduos controladores foi negativamente correlacionado com o sCD14.  Conclusão:  os indivíduos controladores apresentam um perfil cardiovascular diferente dos indivíduos progressores, de acordo com os biomarcadores metabólicos e imunológicos avaliados.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[HIV-1]]></kwd>
<kwd lng="en"><![CDATA[cardiovascular diseases]]></kwd>
<kwd lng="en"><![CDATA[inflammation]]></kwd>
<kwd lng="en"><![CDATA[disease progression]]></kwd>
<kwd lng="es"><![CDATA[VIH-1]]></kwd>
<kwd lng="es"><![CDATA[enfermedades cardiovasculares]]></kwd>
<kwd lng="es"><![CDATA[inflamación]]></kwd>
<kwd lng="es"><![CDATA[progresión de la enfermedad]]></kwd>
<kwd lng="pt"><![CDATA[HIV-1]]></kwd>
<kwd lng="pt"><![CDATA[doenças cardiovasculares]]></kwd>
<kwd lng="pt"><![CDATA[inflamação]]></kwd>
<kwd lng="pt"><![CDATA[progressão da doença]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pelchen-Matthews]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ryom]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Borges]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Duvivier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Stephan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort]]></article-title>
<source><![CDATA[Aids]]></source>
<year>2018</year>
<volume>32</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>2405-16</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antiretroviral Therapy Cohort C. Causes of death in Hiv-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2010</year>
<volume>50</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1387-96</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ingle]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[May]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Gill]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mugavero]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lewden]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Abgrall]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2014</year>
<volume>59</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>287-97</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabin]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy?]]></article-title>
<source><![CDATA[BMC Med]]></source>
<year>2013</year>
<volume>11</volume>
<page-range>251</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuller]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Tracy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Belloso]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[De Wit]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inflammatory and coagulation biomarkers and mortality in patients with HIV infection]]></article-title>
<source><![CDATA[PLoS Med]]></source>
<year>2008</year>
<volume>5</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Group]]></surname>
<given-names><![CDATA[DADS]]></given-names>
</name>
<name>
<surname><![CDATA[Friis-Moller]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Reiss]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sabin]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Monforte]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Class of antiretroviral drugs and the risk of myocardial infarction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>356</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1723-35</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ounjaijean]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kulprachakarn]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Aurpibul]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kaewpoowat]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Boonyapranai]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Chaiwarith]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risks in Asian HIV-infected patients receiving boosted-protease inhibitor-based antiretroviral treatment]]></article-title>
<source><![CDATA[J Infect Dev Ctries]]></source>
<year>2021</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>289-96</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Estrada]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Larrad]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Sanchez]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[de Villar]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Zabena]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy]]></article-title>
<source><![CDATA[Metabolism]]></source>
<year>2006</year>
<volume>55</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>940-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirkman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Mahmud]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Korytkowski]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes Mellitus]]></article-title>
<source><![CDATA[Endocrinol Metab Clin North Am]]></source>
<year>2018</year>
<volume>47</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>81-96</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beraldo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[APD]]></given-names>
</name>
<name>
<surname><![CDATA[Guimaraes]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Vassimon]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Paula]]></surname>
<given-names><![CDATA[FJA]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[DRL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Body fat redistribution and changes in lipid and glucose metabolism in people living with HIV/AIDS]]></article-title>
<source><![CDATA[Rev Bras Epidemiol]]></source>
<year>2017</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>526-36</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mary-Krause]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Partisani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gilquin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cotte]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2012</year>
<volume>55</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>600-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Leary]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Polak]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Kronmal]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Manolio]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Wolfson Jr]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>340</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-22</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petoumenos]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Reiss]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ryom]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rickenbach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sabin]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[El-Sadr]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D: A:D CVD risk equation and general population CVD risk equations]]></article-title>
<source><![CDATA[HIV Med]]></source>
<year>2014</year>
<volume>15</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>595-603</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elite control of HIV infection: implications for vaccines and treatment]]></article-title>
<source><![CDATA[Top HIV Med]]></source>
<year>2007</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>134-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feria]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Taborda]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Rugeles]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV replication is associated to in-flammasomes activation, iL-1beta, IL-18 and caspase-1 expression in GALT and peripheral blood]]></article-title>
<source><![CDATA[PloS One]]></source>
<year>2018</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taborda]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Rugeles]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spontaneous control of HIV replication, but not HAART-induced viral suppression, is associated with lower activation of immune cells]]></article-title>
<source><![CDATA[J Acquir Immune Defic Syndr]]></source>
<year>2014</year>
<volume>66</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>365-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taborda]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rugeles]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Higher frequency of NK and CD4+ T-Cells in mucosa and potent cytotoxic response in HIV controllers]]></article-title>
<source><![CDATA[PloS one]]></source>
<year>2015</year>
<volume>10</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friis-Moller]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Thiebaut]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Reiss]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Monforte]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[De Wit]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study]]></article-title>
<source><![CDATA[Eur J Cardiovasc Prevent Rehab]]></source>
<year>2010</year>
<volume>17</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>491-501</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[NI]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Rondón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validación de los modelos de predicción de Framingham y PROCAM como estimadores del riesgo cardiovascular en una población colombiana]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2014</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>202-12</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[ÁA]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Ávila]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Higuera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[ÁJ]]></given-names>
</name>
<name>
<surname><![CDATA[Aschner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: evaluación del riesgo cardiovascular]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2015</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>263-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marin-Palma]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Cardona-Arias]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Urcuqui-Inchima]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lower high-density lipoproteins levels during human immunodeficiency virus type 1 infection are associated with increased inflammatory markers and disease progression]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>1350</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feinstein]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bahiru]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Achenbach]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Longenecker]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Hsue]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[So-Armah]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2016</year>
<volume>117</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>214-20</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mdodo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Frazier]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Dube]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Mattson]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Sutton]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Brooks]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2015</year>
<volume>162</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>335-44</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Durand]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chartrand-Lefebvre]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Baril]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Trottier]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Trottier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol]]></article-title>
<source><![CDATA[BMC Infect Dis]]></source>
<year>2017</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>611</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Friis-Moller]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Reiss]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Thiebaut]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kirk]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study]]></article-title>
<source><![CDATA[HIV Med]]></source>
<year>2003</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thompson-Paul]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtenstein]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Armon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Palella Jr]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Skarbinski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chmiel]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular Disease Risk Prediction in the HIV Outpatient Study]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2016</year>
<volume>63</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1508-16</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Phan]]></surname>
<given-names><![CDATA[BAP]]></given-names>
</name>
<name>
<surname><![CDATA[Weigel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Scherzer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hur]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-infected adults with carotid atherosclerosis]]></article-title>
<source><![CDATA[Circ Cardiovasc Imaging]]></source>
<year>2017</year>
<volume>10</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nsagha]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Weledji]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Assob]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Njunda]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Tanue]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Kibu]]></surname>
<given-names><![CDATA[OD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon]]></article-title>
<source><![CDATA[BMC Cardiovasc Dis]]></source>
<year>2015</year>
<volume>15</volume>
<page-range>95</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Philip]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CANHEART: is HDL cholesterol a cardiovascular specific risk factor?]]></article-title>
<source><![CDATA[Glob Cardiol Sci Pract]]></source>
<year>2016</year>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Araujo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Banon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Machuca]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perez-Elias]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Casado]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs]]></article-title>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2014</year>
<volume>171</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>545-54</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Post]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Hodis]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Anastos]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2017</year>
<volume>215</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1352-61</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iannello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Boulassel]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Samarani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tremblay]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Toma]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Routy]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2010</year>
<volume>201</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>608-17</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marin-Palma]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Cardona-Arias]]></surname>
<given-names><![CDATA[MJA]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[SDJC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores inmunológicos relacionados con VIH-1 en pacientes colombianos]]></article-title>
<source><![CDATA[Rev Cienc Salud]]></source>
<year>2019</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sereti]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Krebs]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Phanuphak]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fletcher]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Slike]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pinyakorn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2017</year>
<volume>64</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>124-31</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rugeles-López]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Oyuela-Gómez]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Torres]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Jaimes-Barragán]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomarcadores inmunológicos de riesgo cardiovascular en la infección por el virus de inmunodeficiencia humana-1]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2017</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>153-60</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Post]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Deal]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Hodis]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Mack]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV infection is associated with progression of subclinical carotid atherosclerosis]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2015</year>
<volume>61</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>640-50</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
